These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7833135)

  • 1. Testosterone levels as a marker of prognosis to goserelin treatment in metastatic breast cancer.
    Secreto G; Boracchi P; Buzzoni R; Venturelli E; Cavalleri A; Dolci S
    Eur J Cancer; 1994; 30A(11):1629-31. PubMed ID: 7833135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian function suppression with the gonadotrophin-releasing hormone (GnRH) analogue goserelin in premenopausal advanced breast cancer.
    Bajetta E; Celio L; Zilembo N; Bono A; Galluzzo D; Zampino MG; Longhi A; Ferrari L; Buzzoni R
    Tumori; 1994 Feb; 80(1):28-32. PubMed ID: 8191594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary testosterone as a marker of risk of recurrence in operable breast cancer.
    Ballerini P; Oriana S; Duca P; Martinetti A; Venturelli E; Ferrari L; Dolci S; Secreto G
    Breast Cancer Res Treat; 1993; 26(1):1-6. PubMed ID: 8400317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Goserelin in premenopausal advanced breast cancer: clinical and endocrine evaluation of responsive patients.
    Bajetta E; Zilembo N; Buzzoni R; Celio L; Zampino MG; Colleoni M; Oriana S; Attili A; Sacchini V; Martinetti A
    Oncology; 1994; 51(3):262-9. PubMed ID: 8196909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
    Robertson JF; Blamey RW
    Eur J Cancer; 2003 May; 39(7):861-9. PubMed ID: 12706354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
    Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
    J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.
    Taylor CW; Green S; Dalton WS; Martino S; Rector D; Ingle JN; Robert NJ; Budd GT; Paradelo JC; Natale RB; Bearden JD; Mailliard JA; Osborne CK
    J Clin Oncol; 1998 Mar; 16(3):994-9. PubMed ID: 9508182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
    Jonat W
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer--a 5-year experience and further endocrine therapies. Cooperative German Zoladex Study Group.
    Kaufmann M; Jonat W; Schachner-Wünschmann E; Bastert G; Maass H
    Onkologie; 1991 Feb; 14(1):22-4, 26-8, 30. PubMed ID: 1829149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
    Kim JY; Im SA; Jung KH; Ro J; Sohn J; Kim JH; Park YH; Kim TY; Kim SB; Lee KS; Kim GM; Kim SH; Kim S; Ahn JS; Lee KH; Ahn JH; Park IH; Im YH;
    Eur J Cancer; 2018 Nov; 103():127-136. PubMed ID: 30223226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
    Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
    Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Goserelin plus anastrozole in the treatment of premenopausal patients with metastatic breast cancer].
    Yao SY; Xu BH; Li Q; Zhang P; Wang JY; Yuan P; Ma F; Cai RG
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(8):526-8. PubMed ID: 20367963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
    Perachino M; Cavalli V; Bravi F
    BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology.
    Buzzoni R; Biganzoli L; Bajetta E; Celio L; Fornasiero A; Mariani L; Zilembo N; Di Bartolomeo M; Di Leo A; Arcangeli G
    Br J Cancer; 1995 May; 71(5):1111-4. PubMed ID: 7734310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
    Carlson RW; Theriault R; Schurman CM; Rivera E; Chung CT; Phan SC; Arun B; Dice K; Chiv VY; Green M; Valero V
    J Clin Oncol; 2010 Sep; 28(25):3917-21. PubMed ID: 20679610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).
    von Minckwitz G; Graf E; Geberth M; Eiermann W; Jonat W; Conrad B; Brunnert K; Gerber B; Vescia S; Wollert J; Kaufmann M
    Eur J Cancer; 2006 Aug; 42(12):1780-8. PubMed ID: 16765589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.
    Cheer SM; Plosker GL; Simpson D; Wagstaff AJ
    Drugs; 2005; 65(18):2639-55. PubMed ID: 16392882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer.
    von Minckwitz G; Loibl S; Jackisch C; Paepke S; Nestle-Kraemling C; Lux MP; Maass N; Schmutzler R; du Bois A; Wallwiener D; Vescia S; Budischewski K; Kaufmann M
    Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2141-9. PubMed ID: 21795500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.